Epinephrine has been the first-line treatment for anaphylaxis for more than a century. The medication is well understood, generic, and inexpensive. The problem has never been the drug. The problem has always been getting it into the body fast enough — and the dominant solution, the spring-loaded intramuscular auto-injector, comes with a stubborn list of barriers that we see in clinic every week.
The list goes like this. Needles frighten a meaningful subset of patients and caregivers. Auto-injectors are bulky enough that teenagers leave them at home. Hesitation about "stabbing" a child delays the dose. And a non-trivial number of devices are deployed incorrectly — into a thumb instead of a thigh — under the stress of a real reaction. None of this is the medication's fault. All of it is the delivery system.
Neffy is a single-dose intranasal epinephrine spray approved for the emergency treatment of allergic reactions, including anaphylaxis. It is the first needle-free option for delivering epinephrine in this setting, and it represents a meaningful broadening of how anaphylaxis preparedness can look for the right patient.
How it works
The device resembles a common single-dose nasal spray — a small, pocket-sized unit with one actuation. A patient or caregiver inserts the tip into one nostril and presses the plunger firmly. The spray delivers a fixed dose of epinephrine through the rich vascular bed of the nasal mucosa, where it is absorbed into the bloodstream within minutes.
Pharmacokinetic and pharmacodynamic studies comparing intranasal Neffy to intramuscular auto-injectors have shown that blood epinephrine levels and physiological response (heart rate, blood pressure) are broadly comparable. In some scenarios, the nasal route has been shown to reach therapeutic levels in a timeframe similar to — or in some patient sub-populations faster than — the intramuscular route, particularly in patients with thicker subcutaneous tissue at the typical thigh injection site.
One actuation delivers a single dose. As with auto-injectors, a second dose can be given (using the second device the patient carries) if symptoms have not improved within five to ten minutes.
Who is a candidate?
Neffy is approved for adults and paediatric patients above a minimum body weight threshold. Specific weight cutoffs and per-age dosing should be confirmed at the time of prescription against the current label; our team reviews this and individual fit at each consultation.
In our clinic, the patients most commonly interested in switching to — or supplementing with — Neffy fall into a few groups:
- Needle-phobic patients and caregivers. The single most common barrier to timely auto-injector use is hesitation. Removing the needle from the equation removes the hesitation.
- Teenagers and young adults. Adherence with carrying an EpiPen drops sharply through adolescence. A pocket-sized nasal spray looks more like a lip-balm than a medical device — and it gets carried.
- Patients with higher body-mass index. Standard auto-injector needles may not reliably reach muscle through thicker subcutaneous tissue at the outer thigh; intranasal delivery sidesteps that question.
- Schools, workplaces, and travel kits. A device anyone can use with minimal training is easier to standardise across a school first-aid kit, an office, or a stocked travel pack.
Where the trade-offs are
Neffy is not a universal upgrade. There are real considerations to weigh:
- Nasal congestion does not appear to meaningfully block absorption in studies done so far — but patients with significant nasal pathology, recent nasal surgery, or active polyps should discuss this with their specialist.
- Storage and stability conditions are similar to auto-injectors. Both are sensitive to extremes of heat and cold; both have a shelf life.
- Cost and insurance coverage vary. As a newer product, formulary coverage is still evolving — we help patients navigate this at the time of prescription.
- Weight cut-offs apply. For the smallest paediatric patients, traditional lower-dose auto-injector epinephrine remains the standard.
- Behavioural muscle memory. A patient who has been confidently trained on an auto-injector for years should not be switched casually — the goal is rapid, correct administration in a real emergency, whichever device the patient knows best.
The clinical conversation
The right question is not "Neffy or EpiPen?" It is "what is the patient most likely to actually use, correctly, in the moment?" For many patients that answer is still an auto-injector. For an increasing share — particularly adolescents, the needle-phobic, and patients whose body habitus makes intramuscular delivery uncertain — the right answer is a nasal spray, often carried alongside an auto-injector as a backup.
The best epinephrine is the one a patient and their caregivers will reach for without hesitation.
At MED1, every anaphylaxis consultation includes a discussion of which device fits the specific patient's life, in-clinic training on whatever they leave with, a written emergency action plan that reflects their device, and follow-up to confirm comfort with technique before the next potential exposure. We handle the prescription, work with the family on insurance coverage, and stay in touch.
Carrying epinephrine is a discipline. Anything that makes that discipline easier to maintain is, in clinical terms, life-saving.